Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

被引：0
|
作者：
Simon J. B. Aylwin
Istvan Bodi
Ronald Beaney
机构：
[1] King’s College Hospital,Department of Endocrinology
[2] King’s College Hospital,Department of Clinical Neuropathology
[3] Guy’s & St Thomas’ Hospital Cancer Centre,Department of Neuro
来源：
Pituitary | 2016年 / 19卷
关键词：
Vemurafenib; Craniopharyngioma; Prolactinoma; BRAF Inhibitor; BRAF V600E Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：544 / 546
页数：2
相关论文
共 50 条
  • [21] Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma
    Heakal, Yasser
    Kester, Mark
    Savage, Scott
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (11) : 1399 - 1405
  • [22] Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib
    Ansai, Osamu
    Fujikawa, Hiroki
    Shimomura, Yutaka
    Abe, Riichiro
    JOURNAL OF DERMATOLOGY, 2017, 44 (03): : E15 - E16
  • [23] Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Bradley, William D.
    Lee, Richard J.
    Schostack, Kathleen
    Simcox, Mary Ellen
    Kopetz, Scott
    Heimbrook, David
    Lestini, Brian
    Bollag, Gideon
    Su, Fei
    CANCER RESEARCH, 2012, 72 (03) : 779 - 789
  • [24] Exceptional Response of Papillary Craniopharyngioma to Targeted Therapy
    Brastianos, Priscilla Kaliopi
    Shankar, Ganesh
    Gill, Corey
    Taylor-Weiner, Amaro
    Panka, David
    Sullivan, Ryan
    Louis, David
    Santagata, Sandro
    Cahill, Daniel
    Curry, William
    Barker, Frederick
    JOURNAL OF NEUROSURGERY, 2015, 123 (02) : A511 - A511
  • [25] Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (PLX4032)
    Su, F.
    Yang, H.
    Higgins, B.
    Kolinsky, K. D.
    Packman, K.
    Kim, M.
    Lestini, B. J.
    Bollag, G.
    Heimbrook, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Dupuytren's contractures associated with the BRAF inhibitor vemurafenib: A case report
    Chan S.W.
    Vorobiof D.A.
    Journal of Medical Case Reports, 9 (1)
  • [27] CHARACTERIZATION OF RESISTANCE MECHANISMS TO THE BRAF INHIBITOR VEMURAFENIB (PLX4032)
    Azimi, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 23 - 23
  • [28] Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease
    Gupta, Adit
    Yeganeh, Amir
    Rootman, Daniel
    Goldberg, Robert
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2017, 33 (06): : E138 - E139
  • [29] BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
    Koya, Richard C.
    Mok, Stephen
    Otte, Nicholas
    Blacketor, Kevin J.
    Comin-Anduix, Begonya
    Tumeh, Paul C.
    Minasyan, Aspram
    Graham, Nicholas A.
    Graeber, Thomas G.
    Chodon, Thinle
    Ribas, Antoni
    CANCER RESEARCH, 2012, 72 (16) : 3928 - 3937
  • [30] Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
    Sondermann, Wiebke
    Griewank, Klaus G.
    Schilling, Bastian
    Livingstone, Elisabeth
    Leyh, Julia C.
    Rompoti, Natalia
    Cosgarea, Ioana
    Schimming, Tobias
    Schadendorf, Dirk
    Zimmer, Lisa
    Hillen, Uwe
    PLOS ONE, 2015, 10 (04):
12345